US-based, Observational, Drug Registry of Opsumit (Macitentan) New Users in Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms OPUS
- Sponsors Actelion Pharmaceuticals
- 07 Dec 2017 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
- 07 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 30 Apr 2018.
- 24 May 2017 Results (n=688;data cut off:17 April 2016) assessing patients characteristics,treatment patterns and safety presented at the 113th International Conference of the American Thoracic Society.